Corbus Q4 net loss $20.6M; cash $163.3M into 2028; key CRB-701/913 catalysts mid-2026

Corbus Pharmaceuticals Holdings, Inc.

Q4 2025 net loss $20.6M ($1.25/share) vs $9.5M ($0.78) in Q4 2024; operating expenses rose to $22.0M.
Cash $163.3M at Dec 31, 2025; extended runway into 2028 after $75M public offering in Q4.
CRB-701 Phase 1/2 unconfirmed ORR: HNSCC 47.6%, cervical 37.5%; monotherapy data and FDA protocol discussions expected mid-2026.
CRB-913 Phase 1a: 2.9% placebo-adjusted weight loss at 14 days; Phase 1b CANYON-1 (n=240) results due summer 2026.
CRB-601 deprioritized; no further patient enrollment. Pipeline updates from ESMO 2025 and SITC 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Corbus Pharmaceuticals Holdings, Inc. reported fourth quarter and year ended December 31, 2025 results: net income net loss of approximately $20.6 million, or a net loss per basic and diluted share of $1.25, EPS net loss per basic and diluted share of $1.25.

Period: fourth quarter and year ended December 31, 2025
Net income: net loss of approximately $20.6 million, or a net loss per basic and diluted share of $1.25
EPS: net loss per basic and diluted share of $1.25
Result: reported results

Exact text from the filing

The Company reported a net loss of approximately $20.6 million, or a net loss per basic and diluted share of $1.25, for the three months ended December 31, 2025, compared to a net loss of $9.5 million, or a net loss per basic and diluted share of $0.78, for the three months ended December 31, 2024.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Corbus Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-097582

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.